Search

Your search keyword '"Schetelig, Johannes"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Schetelig, Johannes" Remove constraint Author: "Schetelig, Johannes" Publisher nature publishing group uk Remove constraint Publisher: nature publishing group uk
32 results on '"Schetelig, Johannes"'

Search Results

1. How risky is a second allogeneic stem cell transplantation?

2. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

7. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

8. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

9. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

10. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

11. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

16. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

17. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS

18. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

19. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

20. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

21. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

22. The clinical mutatome of core binding factor leukemia

24. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

25. Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial

26. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

27. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

28. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

29. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

31. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

32. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Catalog

Books, media, physical & digital resources